Stelfonta is a drug owned by QBIOTICS GROUP LTD. It is protected by 1 US drug patent filed in 2030. All patents are active. Details of Stelfonta’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US8598229 | Active | |
Exclusivity Information
Stelfonta holds 1 exclusivity out of which 1 has expired. Details of Stelfonta's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Nov 16, 2025 |
About Stelfonta
Stelfonta is a drug
owned by QBIOTICS GROUP LTD.
Stelfonta uses
Tigilanol Tiglate as the active
ingredient.
Active Ingredient:
Stelfonta uses
Tigilanol Tiglate as the active ingredient.
Check out other Drugs and Companies using
Tigilanol Tiglate ingredient.